



UNDERSTANDING NEUROTOXICITY ASSAYS AND INTERSPECIES DIFFERENCES TO ADDRESS ATTRITION IN DRUG DISCOVERY

Drug Discovery Toxicology Specialty Section (DDTSS) Hosted Webinar
Thursday April 15, 2021 @ 2 pm ET

AGENDA

- ① **Welcome**
- ① **Introductions**
- ① **Dr. Thomas Hartung presentation**
- ① **Dr. Remco Westerink presentation**
- ① **Q & A**

MODERATORS



DDTSS, Councilor
Pankajini Mallick
Neurocrine Biosciences



**DDTSS,
Postdoctoral
Representative**
Monica Langley
Mayo Clinic


THOMAS HARTUNG, MD, PHD

Doerenkamp-Zbinden-Chair for Evidence-based Toxicology

Department of Environmental Health and Engineering

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

- Joint appointment at the Whiting School of Engineering
- Joint appointment for Molecular Microbiology and Immunology at the Bloomberg School
- Adjunct affiliate professor at Georgetown University, Washington D.C.
- Joint appointment as Professor for Pharmacology and Toxicology at University of Konstanz, Germany
- Director of Centers for Alternatives to Animal Testing (CAAT)
- Headed the Human Toxome project (NIH Transformative Research Grant)
- Chief Editor of *Frontiers in Artificial Intelligence*.





REMCO WESTERINK, PHD


European Registered Toxicologist
Associate Professor
Neurotoxicology Research Group
Institute for Risk Assessment Sciences (IRAS)
Utrecht University

Head of the Neurotoxicology Research Group (IRAS-Utrecht University)
Recipient 'Willy van Heumen' award for animal-free research (2019)
Editor in Chief NeuroToxicology (Elsevier)
Editorial Board member Toxicology In Vitro (Elsevier) and Toxics (MDPI)
Past President of the International Neurotoxicology Association

Research focus:

Investigate potential adverse effects of exogenous substances on the brain cellular and understand the molecular mechanisms of action of toxic substances on the nervous system.

Developed novel in vitro tools and methods to assess neurotoxicity that allows investigation of adverse outcome pathways (AOPs) that integrate cellular toxicity and adverse human outcomes, thereby translating these findings into practice and policy.



QUESTIONS?
